Showing papers by "Hiroshi Inoue published in 2012"

Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry

Abstract: Background—There is a paucity of international data on the various types of atrial fibrillation (AF) outside the highly selected populations from randomized trials. This study aimed to describe patient characteristics, risk factors, comorbidities, symptoms, management strategy, and control of different types of AF in real-life practice. Methods and Results—Real-life global survey evaluating patients with atrial fibrillation (RealiseAF) was a contemporary, large-scale, cross-sectional international survey of patients with AF who had ≥1 episode in the past 12 months. Investigators were randomly selected to avoid bias. Among 9816 eligible patients from 831 sites in 26 countries, 2606 (26.5%) had paroxysmal, 2341 (23.8%) had persistent, and 4869 (49.6%) had permanent AF. As AF progressed from paroxysmal to persistent and permanent forms, the prevalence of comorbidities, such as heart failure (32.9%, 44.3%, and 55.6%), coronary artery disease (30.0%, 32.9%, and 34.3%), cerebrovascular disease (11.7%, 10.8%, an...

Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry

Abstract: Background Rate control and rhythm control are accepted management strategies for atrial fibrillation (AF). Objective RealiseAF aimed to describe the success of either strategy and the impact of control on symptomatic status of patients with AF. Methods This international, observational, cross-sectional survey of patients with any history of AF in the previous year, recorded AF characteristics, management and frequency of control (defined as sinus rhythm or AF with resting heart rate ≤80 bpm). Results Overall, 9665 patients were evaluable for AF control, with 59.0% controlled (sinus rhythm 26.5%, AF ≤80 bpm 32.5%) and 41.0% uncontrolled. Symptom prevalence in the previous week was lower in controlled than uncontrolled AF (55.7% vs 68.4%; p I) was seen in 67.4% of patients with controlled AF and 82.1% of patients with uncontrolled AF (p Conclusion AF control is not optimal. Control appears to be associated with fewer symptoms and better QoL, but even patients with controlled AF have frequent symptoms, functional impairment, altered QoL and cardiovascular events. New treatments are needed to improve control and minimise the functional and QoL burden of AF.

Guidelines for Risks and Prevention of Sudden Cardiac Death (JCS 2010) : Digest Version

Abstract: The best way to prevent sudden death is predicting the occurrence of sudden death and providing appropriate preventive measures. Since many cases of sudden death are arrhythmic death, the present guidelines describe disease conditions and typical clinical findings that may cause arrhythmic death and how to prevent sudden deaths in patients with such predicted findings. Since ventricular tachyarrhythmias (VTA) including ventricular fibrillation (VF) play an important role in the development of arrhythmic death, and the benefits of implantable cardioverter defibrillator (ICD) in preventing sudden death due to tachycardia have been demonstrated, the present guidelines mainly discuss the use of ICD in the treatment of potentially fatal tachycardia. Severe bradycardia and asystole, which also may cause sudden death, are described in the present guidelines as needed in relation to pathological conditions and diseases known to lead to bradycardia and asystole. The present guidelines is partly revised and reflect the newest findings to be included to the guidelines for the non-pharmacological and pharmacological treatment of arrhythmia of which the Japanese Circulation Society (JCS) are currently revising. The present guidelines are written mainly for the use of cardiologists since pathological conditions and diseases that may cause arrhythmic death must be carefully assessed by expert cardiologists, and since ICD therapy, the most imporIntroduction to the Revised Guidelines